Potential FDA approval for Supernus’s SPN-830 in Parkinson’s but challenges remain

On 9 October, Supernus Pharmaceuticals announced that it had resubmitted a new drug application (NDA) for its subcutaneous apomorphine infusion device (SPN-830) for the continuous treatment of motor fluctuations in Parkinson’s disease (PD).

However, as advancement in drug formulations and delivery systems is one of the most rapidly changing areas in PD treatment, SPN-830 is set to enter a fiercely competitive space.